

MICRUS ENDOVASCULAR CORP

Form 8-K

July 06, 2006

**Table of Contents**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
Date of Report (Date of Earliest Event Reported): July 6, 2006**

**Micrus Endovascular Corporation**

(Exact name of registrant as specified in its charter)

**000-51323**

(Commission File Number)

**Delaware**

(State or Other Jurisdiction of  
Incorporation)

**23-2853441**

(I.R.S. Employer Identification No.)

**821 Fox Lane**

**San Jose, California 95131**

(Address of principal executive offices, including zip code)

**(408) 433-1400**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01. Other Events

Item 9.01. Financial Statements and Exhibits

SIGNATURE

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 8.01. Other Events.**

On July 6, 2006, Micrus Endovascular Corporation ( Micrus ) issued a press release, announcing its expected financial results for the fiscal quarter ended June 30, 2006. A copy of this earnings release is attached as Exhibit 99.1 hereto.

Exhibit 99.1 contains forward-looking statements within the meaning of the federal securities laws. These statements are present expectations, and are subject to the limitations listed therein and in Micrus' other SEC reports, including that actual events or results may differ materially from those in the forward-looking statements.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit</b>	<b>Description</b>
99.1	Press Release dated July 6, 2006

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MICRUS ENDOVASCULAR  
CORPORATION  
(Registrant)

Date: July 6, 2006

By: /s/ Robert A. Stern

Robert A. Stern  
Executive Vice President, Chief  
Financial  
Officer, and Secretary

-2-

---

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated July 6, 2006

-3-